Periodic Reporting for period 1 - EIS (An innovative, effective and minimally-invasive retinal cell therapy combined with a new injection system for treatment of retinal degenerative diseases.)
Reporting period: 2019-11-01 to 2020-02-29
EIS is a novel delivery system for delivery of advanced retinal therapies into the back of the eye. The device encompasses a minimally-invasive injector and a fixation tool, featuring a unique access method through the suprachoroidal space and the matrix between the choroidal blood vessels. It is an effective retinal delivery method with wide drug distribution over 80% which leads to minimal surgeries needed for treatment.
Identifying the need, Everads developed the safe, minimally invasive and effective device to deliver targeted therapy, potentially improving the clinical outcome. The EIS delivery system has minimal side effects and will drastically improve patient's quality of life. It allows the patients who often tend to be elderly be more independent. Everads Therapy thus envisions a future where safer and effective therapy delivery techniques will enable better outcomes for retinal degeneration treatment.
The overall objectives of the project include, defining a minimum viable product, establish a feasible product development plan and industrialisation strategy, plan demonstration and validation trials and analyse risks and opportunities.
The total costs of managing the consequences of severe/late-stage AMD alone in the EU was estimated to be €89.46 billion per year among adults aged 50 years and older. With the use of the EIS combined delivery, these costs can be reduced or even completely eliminated due to multiple advantages generated by Everads novel delivery system. Directly EIS commercialization will create 32 high skilled jobs in Europe.